Member Info for Bobbler

Aber, I don’t think any company is going make an offer in the £5-6 range per share, with a sp 40p they would probably offer 150-200% premium, say £1.50 ish per share. Without data there’s unlikely to be any offers as yet. Just amazed how much a £3m equity deal has wiped off the market cap. If that was the best offer on the table……….

It’s been a long time getting here. However from reading the below, clearly Sareum have tried to overcome as many of the common areas of failure. Personally I feel they have taken the correct approach and as such we have a better chance of success. Have a good weekend all.

Good read ref Trials failure. Particular mention of kinase inhibitor (2.2)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/#:~:text=It%20is%20also%20worth%20noting,candidates%20in%20the%20preclinical%20stages.

Unfortunately the SRA737 deal won’t impress to many people. Upfront is low and the upper figures are worth nothing until something materialises. Having said that, I don’t feel it’s a bad deal. GSK may have returned it but that doesn’t mean there’s no potential. Sierra paid Gilead an upfront fee of $3 million for momelotinib and GSK paid $2 billion to get hold of it. Back to the waiting game….. red or black?

Do you mean 60p? They hold circa 1 million shares after consolidation

I imagine it was a very hard set of trials.!

Gate was left open at the clown farm

Was it you Puma?

👍 cheers

Yes mate, good as gold 👍

Rayboy, I had an uninvited cuddle from the grim reaper shortly after the spike. So my priorities changed dramatically, I still believe we will get there but I don’t loose any sleep over it.

Rayboy, that’s exactly what I tell my missus when she calls me a greedy ships anchor for not selling!

Spot on Luton. It is what it is. Do I wish I’d sold and banked c£400k during the covid spike?, in hindsight yes. But at the end of the day it’s a gamble and hopefully we will one day beat the previous highs, but who knows. It’s AIM, it’s a gamble, isn’t that why most of us invested in the first place? Adds a bit of excitement to life.

Basser, I noticed that as well. In the Past Physiomics collaborated with Sareum, the ICR and CRT.

My apologies Ben, certainly not deliberate

HBD, thanks for posting.

What a beautiful read on a beautiful Sunny morning:

“ members of the SRC have decided that it is appropriate to initiate Part 4 of the study and the doses that should be used. The doses that are selected for Part 4 of the study will have been demonstrated to be well tolerated, and exposure at those doses would not have exceeded that seen at the no-observed-adverse-effect level (NOAEL) (in the most sensitive toxicology species, the dog) in other Parts of the study. Recruitment to Cohort Psoriasis Dose ii may start as soon as recruitment to Cohort Psoriasis Dose i has completed.”

MAJW why do you never answer my question ref Kodal’s deal with RF? Is it because they have some very well on a very similar facility, 113% up year to date, death spiral? I think not.

Estimated worldwide to be 125 million people suffering with Psoriasis.

Been a busy news week, I wonder if we will see another RNS today.

Clearly there is an appetite for buying again.

To be honest I've no idea! :-0